VKTX Viking Therapeutics Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
15:36
Aug 11
Aug 11
Short-term hold on bullish chart setup
Author holds VKTX as a short-term trade citing favorable chart setup; technical observation only, no fundamental catalyst stated.
LOW
18:40
Jul 12
Jul 12
Named in a health sector thematic basket the author describes as areas of value they are.
Named in a health sector thematic basket the author describes as areas of value they are rotating across.
MED
13:00
Jun 30
Jun 30
Author names VKTX as a medium-term favorite pick when asked to choose among a group of five.
Author names VKTX as a medium-term favorite pick when asked to choose among a group of five names; low-conviction bullish candidate with no explicit catalyst stated.
MED
11:56
Jun 30
Jun 30
Speaker presents this as a top pick with bullish catalysts (oral Phase 3, chart breakout.
Speaker presents this as a top pick with bullish catalysts (oral Phase 3, chart breakout, target 120), no personal position stated.
MED
10:27
Jun 29
Jun 29
Author expresses love for ABCL and VKTX with bullish commentary on potential and chart.
Author expresses love for ABCL and VKTX with bullish commentary on potential and chart, but no explicit position language or forward call, so both are watch.
LOW
14:40
Jun 27
Jun 27
Listed as part of thematic sector overview in author's market read.
Listed as part of thematic sector overview in author's market read, no directional view expressed.
LOW
00:38
Jun 21
Jun 21
Author asks if the recipient has looked into VKTX or ABCL.
Author asks if the recipient has looked into VKTX or ABCL, a research inquiry without a directional position or endorsement.
LOW
00:20
Jun 20
Jun 20
Small speculative basket of "undervalued plays" held within the ~5% crypto/misc allocation.
Small speculative basket of "undervalued plays" held within the ~5% crypto/misc allocation; author characterizes these as undervalued but provides no specific catalyst beyond general sentiment recovery.
MED
09:04
Jun 10
Jun 10
The author presents a large diversified basket of favorite names across sectors as where they.
The author presents a large diversified basket of favorite names across sectors as where they are positioned for the next few years, but the 30+ tickers default to watch due to the basket size rule.
17:37
Jun 09
Jun 09
Author discloses current positioning in VKTX as a Health name.
Author discloses current positioning in VKTX as a Health name, framing the dip as a buying opportunity with a multi-year hold thesis.
MED
08:37
Jun 08
Jun 08
Author provides a broad thematic basket of strong buy and buy ratings.
Author provides a broad thematic basket of strong buy and buy ratings with enablers/beneficiaries framing, explicitly recommends selling Carvana, but the large list defaults to watch except for the explicit sell call on CVNA.
LOW
23:13
Jun 05
Jun 05
Author lists VKTX in a health/biotech basket with a blanket current-holdings disclosure.
Author lists VKTX in a health/biotech basket with a blanket current-holdings disclosure; thematic basket per speaker note, no ticker-specific thesis.
LOW
22:27
Jun 02
Jun 02
Author clarifies that despite past bearishness, their recent positions in Viking Therapeutics.
Author clarifies that despite past bearishness, their recent positions in Viking Therapeutics have been long, defending themselves against being labeled a permabear.
04:37
May 26
May 26
Buy VKTX as part of an active short-term trade portfolio.
Buy VKTX as part of an active short-term trade portfolio; author sets explicit upside price target of $35, indicating a committed long position with defined exit.
MED
13:09
Apr 27
Apr 27
Adam May boasts a strong short-selling track record with past wins on NTLA, HIMS, VKTX.
Adam May boasts a strong short-selling track record with past wins on NTLA, HIMS, VKTX, and IOVA, and expresses a forward-looking bearish view on ORKA.
HIGH
22:11
Apr 26
Apr 26
Explicit portfolio list: 'If I had to hold 10 stocks for 2026'.
Explicit portfolio list: 'If I had to hold 10 stocks for 2026' — first-person commitment to holding $VKTX.
MED
15:08
Apr 21
Apr 21
Speaker found niche peptide stock $VKTX with detailed thesis.
Speaker found niche peptide stock $VKTX with detailed thesis: dual GLP-1/GIP agonist (sub+oral) attacking $100B+ obesity market, both VANQUISH-1 and VANQUISH-2 Phase 3 trials fully enrolled.
MED
08:54
Aug 20
Aug 20
Notes analysts view recent sell-off as exaggerated.
Notes that 10 out of 11 analysts believe the recent sell-off is exaggerated and the underlying data is good.
MED
14:46
Aug 19
Aug 19
Advises against investing in pre-commercial biotech.
Author strongly advises against investing in pre-commercial biotech, comparing the risk to gambling at a casino.
MED
08:34
Aug 19
Aug 19
Speculates on potential acquisition by NVO.
Speculates an acquisition by NVO would make sense given the economic advantages of small molecule GLP1s.
LOW
20:52
Dec 18
Dec 18
Long VKTX for best-in-class market candidates
Author discloses a long position in VKTX at $38, arguing its best-in-class candidates for a $130bn market justify a higher valuation.
HIGH
17:36
Aug 26
Aug 26
Author discloses existing VKTX long position
Author discloses an existing position in VKTX while expressing caution regarding overly bullish retail sentiment.
MED
14:28
Jun 14
Jun 14
Observes post-approval biotech price drops awaiting buyouts.
Observes pattern of biotech stocks dropping to 200-day moving average post-approval while investors await buyouts.
MED
16:42
Jun 05
Jun 05
Notes extreme price volatility despite strong data.
Observes extreme price volatility in VKTX despite consistently strong data, noting market irrationality.
LOW
13:25
Jun 04
Jun 04
High buyout probability for best-in-class obesity therapy.
Expects a high probability of a buyout for VKTX, driven by its best-in-class obesity and NASH clinical trials and the massive sales potential in the GLP-1 market.
HIGH
18:08
Mar 15
Mar 15
VKTX is too risky at current levels
Argues VKTX is too risky with a high probability of failure, suggesting investors are blinded by the GLP-1 total addressable market.
MED
About VKTX Analyst Coverage
Buzzberg tracks VKTX (Viking Therapeutics) across 3 sources. 9 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (35%). 26 total trade ideas tracked. Latest voices: __con_, A May MD, moodywriter13.